1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
    Meeting Abstract

    Saura Manich, C.; Modi, S.; Krop, I.; Park, Y. H.; Kim, S. B.; Tamura, K.; André, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+ / human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC)
    Meeting Abstract

    Chandarlapaty, S.; Linden, H. M.; Neven, P.; Petrakova, K.; Bardia, A.; Kabos, P.; Braga, S.; Boni, V.; Pelekanou, V.; Ternès, N.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+ / human epidermal growth factor receptor 2-negative (HER2-) PIK3CA-mutated advanced breast cancer
    Meeting Abstract

    Campone, M.; Bardia, A.; Kabos, P.; Chandarlapaty, S.; Neven, P.; Boni, V.; Lord, S.; Cartot-Cotton, S.; Celanovic, M.; Gosselin, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC)
    Meeting Abstract

    O'Shaughnessy, J.; Brufsky, A.; Rugo, H. S.; Tolaney, S. M.; Diab, S.; Punie, K.; Sardesai, S.; Hamilton, E.; Loirat, D.; Traina, T. A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer
    Meeting Abstract

    Tsai, M.; Han, H. S.; Montero, A. J.; Tkaczuk, K. H.; Assad, H.; Pusztai, L.; Hurvitz, S. A.; Wilks, S. T.; Specht, J. M.; Nanda, R.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC)
    Meeting Abstract

    Swain, S. M.; Tan, A.; Gianni, L.; Kümmel, S.; Dang, C.; Schneeweiss, A.; O'Shaughnessy, J.; Liu, H.; Aguila, C.; Heeson, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • An open-label, phase II, multicenter, single-arm study of induction and concurrent vismodegib combined with curative-intent radiation therapy for locally advanced basal cell carcinoma
    Meeting Abstract

    Yom, S.; Arron, S.; Ho, A.; Algazi, A.; Dunn, L.; Tsai, C. J.; Humphries, A.; Hultman, C.; Grekin, R.; Knott, P. D.; more...
    American Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Dynamic circulating tumor DNA interim results from the ALKternate clinical trial
    Meeting Abstract

    Itchins, M.; Liang, S.; Barnes, T.; Marx, G.; Chin, V.; Kao, S.; Yip, P. Y.; Nagrial, A.; Peters, G.; Bray, V.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I/II study
    Journal Article

    Kelley, R. K.; Sangro, B.; Harris, W.; Ikeda, M.; Okusaka, T.; Kang, Y. K.; Qin, S.; Tai, D. W. M.; Lim, H. Y.; Yau, T.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Prospective evaluation of clinical outcomes using a multiplex liquid biopsy targeting diverse resistance mechanisms in metastatic prostate cancer
    Journal Article

    Sperger, J. M.; Emamekhoo, H.; McKay, R. R.; Stahlfeld, C. N.; Singh, A.; Chen, X. E.; Kwak, L.; Gilsdorf, C. S.; Wolfe, S. K.; Wei, X. X.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save